Q12109 (Q12109): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item)
Property / EU contribution
 
5,007,500.0 Czech koruna
Amount5,007,500.0 Czech koruna
UnitCzech koruna
Property / EU contribution: 5,007,500.0 Czech koruna / rank
 
Normal rank
Property / EU contribution
 
200,300.0 Euro
Amount200,300.0 Euro
UnitEuro
Property / EU contribution: 200,300.0 Euro / rank
 
Preferred rank
Property / EU contribution: 200,300.0 Euro / qualifier
 
exchange rate to Euro: 0.04 Euro
Amount0.04 Euro
UnitEuro
Property / EU contribution: 200,300.0 Euro / qualifier
 
point in time: 10 January 2020
Timestamp+2020-01-10T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / budget
 
10,015,000.0 Czech koruna
Amount10,015,000.0 Czech koruna
UnitCzech koruna
Property / budget: 10,015,000.0 Czech koruna / rank
 
Normal rank
Property / budget
 
400,600.0 Euro
Amount400,600.0 Euro
UnitEuro
Property / budget: 400,600.0 Euro / rank
 
Preferred rank
Property / budget: 400,600.0 Euro / qualifier
 
exchange rate to Euro: 0.04 Euro
Amount0.04 Euro
UnitEuro
Property / budget: 400,600.0 Euro / qualifier
 
point in time: 10 January 2020
Timestamp+2020-01-10T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Revision as of 02:52, 12 February 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
No label defined
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    5,007,500.0 Czech koruna
    0 references
    200,300.0 Euro
    10 January 2020
    0 references
    10,015,000.0 Czech koruna
    0 references
    400,600.0 Euro
    10 January 2020
    0 references
    50 percent
    0 references
    30 June 2020
    0 references
    VUAB Pharma a.s.
    0 references
    0 references

    50°9'46.91"N, 14°23'2.26"E
    0 references
    25263
    0 references
    Předkládaný projekt je zaměřen na rozšíření výzkumně-vývojového centra pro urychlení a zkvalitnění vývoje konečné lékové formy léčiv nádorových onemocnění, a to jak originálních, tak generických léčiv, které bylo vybudováno v předchozích letech. a. (Czech)
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/17_165/0015953
    0 references